Impact of the COVID-19 pandemic on symptoms of anxiety and depression and health-related quality of life in older patients with chronic kidney disease

Table 2 Mental wellbeing prior and during COVID-19 pandemic

	Score range^a	n	Prior COVID-19 pandemic	During COVID-19 pandemic	p-value
*Cross-sectional outcomes*
Generic anxiety symptoms
HADS-A score, median (IQR)	0–21	80	–	3.0 (0.0–6.0)
HADS-A score ≥ 8, n (%)		80	–	12 (15%)
*Longitudinal outcomes*
Depressive symptoms
GDS-15 score, median (IQR)^b	0–15	81	0.0 (0.0–3.0)	0.0 (0.0–4.0)	.028
GDS-15 score ≥ 5, n (%)	Yes/no	81	9 (11%)	18 (22%)	.022
HRQoL
MCS, mean (SD)	0–100	80	50.3 (9.6)	50.4 (9.9)	.913
PCS, mean (SD)	0–100	80	40.4 (10.1)	36.1 (10.4)	<.001

Abbreviations: GDS-15 15-item geriatric depression scale, HADS-A anxiety subscale of hospital anxiety and depression scale, HRQoL health-related quality of life, IQR inter-quartile range, MCS mental component summary, PCS physical component summary, SD standard deviation
^aHigher scores indicate more anxiety- or depressive symptoms, or better HRQoL
For n = 23 patients who scored positive on Whooley questions both before and during the pandemic
^bWhere both Whooley questions were answered negative, we assumed GDS-15 score was 0

ISSN: 1471-2318